StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Summit Therapeutics gets $2B AstraZeneca investment, Citi raises target
September 29, 2026 5:03 AM
Citi analyst Yigal Nochomovitz raised the price target on Summit Therapeutics (NASDAQ: SMMT) to $43 from $40, while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
